Approximately one-third of patients with overactive bladder (OAB) experience incontinence, a bothersome symptom with a clear negative effect on quality of life.
Objective:
To assess OAB patients' perceptions of improvements in symptom bother and quality of life after taking solifenacin under conditions reflecting day-today practice.
Methods:
VOLT (the VESIcare Open-Label Trial) was a prospective, open-label study in patients with OAB (defined as urgency, urge urinary incontinence, daytime frequency, or nocturia for ≥3 mo) who were treated with flexibly dosed, once-daily solifenacin for 12 weeks. This study included subjects enrolled in VOLT who, at baseline, had urge incontinence and reported incontinence as their most bothersome symptom. All patients were started on solifenacin 5 mg/day; at week 4, the dosage could be increased to 10 mg/day and at week 8 could be maintained or decreased back to 5 mg/day. Efficacy was assessed by 3 independent patient-reported outcomes: the Patient Perception of Bladder Condition (PPBC) scale, a visual analog scale (VAS) for assessing individual symptoms, and the Overactive Bladder Questionnaire (OAB-q).
Results:
Of the 2205 patients in the VOLT full analysis set, 1586 (71.9%) had urge incontinence at baseline, of which 582 (36.7%) reported incontinence as their most bothersome symptom. In this cohort, mean PPBC score at baseline was 4.6 (indicating moderate-to-severe problems) and at endpoint had decreased significantly to 2.9 (very minor to some minor problems; p < 0.001). At endpoint, 80.4% of patients achieved improvement in their PPBC score. These patients reported significant improvements from baseline in urinary urgency, urge incontinence, frequency, and nocturia on the VAS (p < 0.001) and all OAB-q domains (symptom severity, coping, concern, sleep, social, health-related quality of life) at endpoint (p < 0.001).
Conclusions:
Patients reporting urge incontinence as their most bothersome OAB symptom can be expected to demonstrate significant improvements in multiple patient-related outcomes following treatment with flexibly dosed solifenacin.
AbramsP.Reviewing the ICS 2002 Terminology Report: the ongoing debate. Neurourol Urodyn2006;25:293. DOI 10.1002/nau.20251
2.
TubaroA.Defining overactive bladder: epidemiology and burden of disease. Urology2004;64:2–6. DOI 10.1016/j.urology.2004.10.047
3.
MichelMC, de la RosetteJJ, PiroM, SchneiderT.Comparison of symptom severity and treatment response in patients with incontinent and continent overactive bladder. Eur Urol2005;48:110–5. DOI 10.1016/j.eururo.2004.11.012
4.
WeinAJ, RovnerES. Definition and epidemiology of overactive bladder. Urology2002;60:7–12.
5.
MacDiarmidS, RosenbergM.Overactive bladder in women: symptom impact and treatment expectations. Curr Med Res Opin2005;21:1413–21. DOI 10.1185/030079905X59076
6.
CoyneKS, PayneC, BhattacharyyaSK. The impact of urinary urgency and frequency on health-related quality of life in overactive bladder results from a national community survey. Value Health2004;7:455–63.
7.
CoyneK, RevickiD, HuntT.Psychometric validation of an overactive bladder symptom and health-related quality of life questionnaire: the OAB-q. Qual Life Res2002;11:563–74.
8.
PalmtagH.The patient's perspective: redefining end points. Urology2004;64:17–20. DOI 10.1016/j.urology.2004.10.037
9.
WeinAJ, RovnerES. The overactive bladder: an overview for primary care health providers. Int J Fertil Womens Med1999;44:56–66.
10.
RoeB, MayC.Incontinence and sexuality: findings from a qualitative perspective. J Adv Nurs1999;30:573–9.
11.
HunskaarS, VinsnesA.The quality of life in women with urinary incontinence as measured by the sickness impact profile. J Am Geriatr Soc1991;39:378–82.
12.
WymanJF, HarkinsSW, ChoiSC, TaylorJR, FantlJA. Psychosocial impact of urinary incontinence in women. Obstet Gynecol1987;70:378–81.
13.
IrwinDE, MilsomI, KoppZ, AbramsP, CardozoL.Impact of overactive bladder symptoms on employment, social interactions and emotional well-being in six European countries. BJU Int2006;97:96–100. DOI 10.1111/j.1464-410X.2005.05889.x
14.
AlhassoAA, McKinlayJ, PatrickK, StewartL.Anticholinergic drugs versus non-drug therapies for overactive bladder syndrome in adults (review). Cochrane Database Syst Review2006;4:CD003193. DOI 10.1002/14651858.CD003193.pub3
15.
KobayashiS, IkedaK, MiyataK.Comparison of in vitro selectivity profiles of solifenacin succinate (YM905) and current antimuscarinic drugs in bladder and salivary glands: a Ca2+ mobilization study in monkey cells. Life Sci2004;74:843–53.
16.
OhtakeA, UkaiM, HatanakaT.In vitro and in vivo tissue selectivity profile of solifenacin succinate (YM905) for urinary bladder over salivary gland in rats. Eur J Pharmacol2004:492: 243–50. DOI 10.1016/j.ejphar2004.03.044
17.
CardozoL, LisecM, MillardR.Randomized, double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder. J Urol2004;172:1919–24.
18.
ChappleCR, AranoP, BoschJL, De RidderD, KramerAE, RidderAM. Solifenacin appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a placebo- and tolterodine-controlled phase 2 dose-finding study. BJU Int2004;93:71–7.
19.
ChappleCR, RechbergerT, Al-ShukriS.Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. BJU Int2004;93:303–10. DOI 10.1111/j.1464-410X,2004404606
20.
RosenbergMT, DmochowskiRR. Overactive bladder: evaluation and management in primary care. Cleve Clin J Med2005;72:149–56.
21.
MilsomI, AbramsP, CardozoL, RobertsRG, ThuroffJ, WeinAJ. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int2001;87:760–6.
22.
RodriguezLV, BlanderDS, DoreyF, RazS, ZimmernP.Discrepancy in patient and physician perception of patient's quality of life related to urinary symptoms. Urology2003;62:49–53.
23.
LemackGE, ZimmernPE. Predictability of urodynamic findings based on the Urogenital Distress Inventory-6 questionnaire. Urology1999;54:461–6.
ChappleCR, Martinez-GarciaR, SelvaggiL.A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial. Eur Urol2005;48:464–70. DOI 10.1016/j.eururo.2005.05.015
26.
KelleherCJ, CardozoL, ChappleCR, HaabF, RidderAM. Improved quality of life in patients with overactive bladder symptoms treated with so lifenacin. BJU Int2005;95:81–5. DOI 10.1111/j.1464-410X.2004.05255.x
27.
GarelyAD, KaufmanJM, SandPK, SmithN, AndohM.Symptom bother and health-related quality of life outcomes following solifenacin treatment for overactive bladder, the VESIcare Open-Label Trial (VOLT). Clin Ther2006;28:1935–46. DOI 10.1016/j.clinthera2006.11.010
28.
MatzaLS, ThompsonCL, KrasnowJ, Brewster-JordanJ, ZyczynskiT, CoyneKS. Test–retest reliability of four questionnaires for patients with overactive bladder: the overactive bladder questionnaire (OAB-q), patient perception of bladder condition (PPBC), urgency questionnaire (UQ), and the primary OAB symptom questionnaire (POSQ). Neurourol Urodyn2005;24:215–25. DOI 10.1002/nau.20110
29.
CoyneKS, MatzaLS, KoppZ, AbramsP.The validation of the patient perception of bladder condition (PPBC): a single-item global measure for patients with overactive bladder. Eur Urol2006;49:1079–86. DOI 10.1016/j.eururo.2006.01.007
30.
CoyneKS, MatzaLS, ThompsonCL, KoppZS, KhullarV.Determining the importance of change in the overactive bladder questionnaire. J Urol2006;176:627–32. DOI 10.1016/j.juro.2006.03.088
31.
PleilAM, CoyneKS, ReesePR, JumadilovaZ, RovnerES, KelleherCJ. The validation of patient-rated global assessments of treatment benefit, satisfaction, and willingness to continue—the BSW. Value Health2005;8(suppl 1):S25–34. DOI 10.1111/j.1524-4733.2005.00069.x
32.
WernerM, SchusslerB.Does oral desmopressin (Minirin) enhance the spectrum of treatment for motor urge incontinence in selected women?Presented at the 33rd Annual Meeting of the International Continence Society, Florence, Italy, October 5–9, 2003.
33.
SimaAA, CalvaniM, MehraM, AmatoA.Acetyl-L-carnitine improves pain, nerve regeneration, and vibratory perception in patients with chronic diabetic neuropathy: an analysis of two randomized placebo-controlled trials. Diabetes Care2005;28:89–94.
34.
AbramsP, SwiftS.Solifenacin is effective for the treatment of OAB dry patients: a pooled analysis. Eur Urol2005;48:483–7. DOI 10.1016/j.eururo.2005.06.007
35.
MillardR, HalaskaM, HuangM, RidderA.Efficacy of solifenacin in patients with severe symptoms of overactive bladder: a pooled analysis. Presented at the 35th Annual Meeting of the International Continence Society, Montreal, Canada, August 28'September 2, 2005.
36.
KrauwinkelWJ, SmuldersRA, MulderH, SwartPJ, Taekema-RoelvinkME. Effect of age on the pharmacokinetics of solifenacin in men and women. Int J Clin Pharmacol Ther2005;43:227–38.
37.
WaggA, WyndaeleJJ, SieberP.Efficacy and tolerability of solifenacin in elderly subjects with overactive bladder syndrome: a pooled analysis. Am J Geriatr Pharmacother2006;4:14–24. DOI 10.1016/j.amjopharm.2006.03.004
38.
GarelyA, PartolL.Patient perception of bladder condition is a clinically useful efficacy measure in the management of overactive bladder. Presented at the 32nd Annual Meeting of the International Continence Society, Heidelberg, Germany, August 28–30, 2002.
39.
RicciJA, BaggishJS, HuntTL. Coping strategies and health care–seeking behavior in a US national sample of adults with symptoms suggestive of overactive bladder. Clin Ther2001;23:1245–59.
40.
UshijimaS, UkimuraO, SuzukiK.Impact of bother specific to each symptom of the International Prostate Symptom Score (IPSS) on the Quality of Life (QoL): concomitant evaluation of IPSS with a visual analogue scale (VAS) questionnaire for bother specific to each symptom. Presented at the Joint Meeting of the International Continence Society and UroGynecological Association, Paris, August 25–27, 2004.
41.
BruntonS, KuritzkyL.Recent developments in the management of overactive bladder: focus on the efficacy and tolerability of once daily solifenacin succinate 5 mg. Curr Med Res Opin2005;21:71–80.
